Premium
Standard and intermediate risk acute lymphoblastic leukemia in Poland: A report of the Polish Children's Leukemia/Lymphoma Study Group
Author(s) -
RADWANSKA URSZULA,
MICHALEWSKA DANUTA,
KOLECKI PAWEL,
ARMATA JERZY,
BALWIERZ WALENTYNA,
BOGUSLAWSKAJAWORSKA JANINA,
CHYBICKA ALICJA,
CYKLIS ROMANA,
KOWALCZYK JERZY,
OCHOCKA MARIA,
PAWELEC KATARZYNA,
ROKICKAMILEWSKA ROMA,
SONTAJAKIMCZYK DANUTA,
SLADKOWSKA GRAZYNA,
ZELENAY ELZBIETA
Publication year - 1995
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1995.tb03681.x
Subject(s) - medicine , lymphoblastic leukemia , leukemia , lymphoma , pediatrics , oncology
A total of 527 children with acute lymphoblastic leukaemia (ALL) from the most frequent risk groups: standard risk group (SRG) and intermediate risk group (IRG) were treated between 1987 and 1991 according to an intensified treatment program (based on the BFM protocol) including the use of an intermediate dose of methotrexate in the IRG. A comparison of the treatment results in this group from 513 children treated between 1981 and 1987 indicates that the chance for a 6 year event‐free survival has increased to 73% (previously 55%).